News

Show
news from

Anaveon Announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

Anaveon to present first clinical data from the Phase I/II study of ANV419 at the AACR Annual Meeting 2022

Anaveon to raise CHF 110 million in oversubscribed Series B financing

Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting

Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

Load more

Search